Cisplatin overcomes radiotherapy resistance in OCT4-expressing head and neck squamous cell carcinoma

Bray, 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA. Cancer J Clin, 68, 394, 10.3322/caac.21492 Fakhry, 2018, Head and neck squamous cell cancers in the United States are rare and the risk now is higher among white individuals compared with black individuals, Cancer, 124, 2125, 10.1002/cncr.31322 Argiris, 2019, Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer, J Clin Oncol, 37, 3266, 10.1200/JCO.19.00555 Burtness, 2019, Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study, Lancet (London, England), 394, 1915, 10.1016/S0140-6736(19)32591-7 Forster, 2019, Patritumab or placebo, with cetuximab plus platinum therapy in recurrent or metastatic squamous cell carcinoma of the head and neck: A randomised phase II study, Eur J Cancer, 123, 36, 10.1016/j.ejca.2019.08.017 Klinghammer, 2019, Cetuximab, fluorouracil and cisplatin with or without docetaxel for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CeFCiD): an open-label phase II randomised trial (AIO/IAG-KHT trial 1108), Eur J Cancer, 122, 53, 10.1016/j.ejca.2019.08.018 Mehanna, 2019, Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial, Lancet (London, England), 393, 51, 10.1016/S0140-6736(18)32752-1 Longo, 2020, Head and Neck Cancer, N Engl J Med, 382, 60, 10.1056/NEJMra1715715 Grégoire, 2010, Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol Off J Eur Soc Med Oncol, 21, v184, 10.1093/annonc/mdq185 Nissi, 2021, Recurrence of head and neck squamous cell carcinoma in relation to high-risk treatment volume, Clin Transl Radiat Oncol, 27, 139 Pignon, 2009, Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients, Radiother Oncol, 92, 4, 10.1016/j.radonc.2009.04.014 Forastiere, 2004, Is there a new role for induction chemotherapy in the treatment of head and neck cancer?, J Natl Cancer Inst, 96, 1647, 10.1093/jnci/djh339 Blanchard, 2011, MACH-CH Collaborative group Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site, Radiother Oncol, 100, 33, 10.1016/j.radonc.2011.05.036 Routila, 2021, Evaluation of prognostic biomarkers in a population-validated Finnish HNSCC patient cohort, Eur Arch Oto-Rhino-Laryngology, 278, 4575, 10.1007/s00405-021-06650-7 Carpén, 2018, Presenting symptoms and clinical findings in HPV-positive and HPV-negative oropharyngeal cancer patients, Acta Otolaryngol, 138, 513, 10.1080/00016489.2017.1405279 Ruuskanen, 2018, Outcome of nasopharyngeal carcinoma in Finland: A nationwide study, Acta Oncol, 57, 251, 10.1080/0284186X.2017.1346378 Ventelä, 2015, CIP2A is an Oct4 target gene involved in head and neck squamous cell cancer oncogenicity and radioresistance, Oncotarget, 6, 144, 10.18632/oncotarget.2670 Balboa, 2015, Conditionally Stabilized dCas9 Activator for Controlling Gene Expression in Human Cell Reprogramming and Differentiation, Stem Cell Rep, 5, 448, 10.1016/j.stemcr.2015.08.001 Arjonen, 2020, Image-based ex vivo drug screen to assess targeted therapies in recurrent thymoma, Lung Cancer, 145, 27, 10.1016/j.lungcan.2020.04.036 Reid, 2019, Diversity of cancer stem cells in head and neck carcinomas: The role of HPV in cancer stem cell heterogeneity, plasticity and treatment response, Radiother Oncol J Eur Soc Ther Radiol Oncol, 135, 1, 10.1016/j.radonc.2019.02.016 Guo, 2008, Oct-4 is critical for survival/antiapoptosis of murine embryonic stem cells subjected to stress: effects associated with Stat3/survivin, Stem Cells, 26, 30, 10.1634/stemcells.2007-0401 Wang, 2013, OCT4 promotes tumorigenesis and inhibits apoptosis of cervical cancer cells by miR-125b/BAK1 pathway, Cell Death Dis, 4, e760, 10.1038/cddis.2013.272 Rühle, 2021, De-escalation strategies of (Chemo)radiation for head-and-neck squamous cell cancers—hpv and beyond, Cancers (Basel)., 13, 1, 10.3390/cancers13092204 Chera, 2018, Current Status and Future Directions of Treatment Deintensification in Human Papilloma Virus-associated Oropharyngeal Squamous Cell Carcinoma, Semin Radiat Oncol, 28, 27, 10.1016/j.semradonc.2017.08.001 Gillison, 2019, Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial, Lancet (London, England), 393, 40, 10.1016/S0140-6736(18)32779-X Gallitto, 2019, Trimodality therapy for oropharyngeal cancer in the TORS era: Is there a cohort that may benefit?, Head Neck, 41, 3009, 10.1002/hed.25779 Mydlarz, 2015, The role of surgery for HPV-associated head and neck cancer, Oral Oncol, 51, 305, 10.1016/j.oraloncology.2014.10.005 Bauml, 2019, Cisplatin versus cetuximab with definitive concurrent radiotherapy for head and neck squamous cell carcinoma: An analysis of Veterans Health Affairs data, Cancer, 125, 406, 10.1002/cncr.31816 Ferris, 2016, Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck, N Engl J Med, 375, 1856, 10.1056/NEJMoa1602252 Ruan, 2019, OCT4 accelerates tumorigenesis through activating JAK/STAT signaling in ovarian cancer side population cells, Cancer Manag Res, 11, 389, 10.2147/CMAR.S180418 Chiou, 2008, Positive Correlations of Oct-4 and Nanog in Oral Cancer Stem-Like Cells and High-Grade Oral Squamous Cell Carcinoma, Clin Cancer Res, 14, 4085, 10.1158/1078-0432.CCR-07-4404 Koo, 2015, Oct4 is a critical regulator of stemness in head and neck squamous carcinoma cells, Oncogene, 34, 2317, 10.1038/onc.2014.174 Villodre, 2016, Roles of OCT4 in tumorigenesis, cancer therapy resistance and prognosis, Cancer Treat. Rev, 51, 1, 10.1016/j.ctrv.2016.10.003 Kelland, 2007, The resurgence of platinum-based cancer chemotherapy, Nat Rev Cancer, 7, 573, 10.1038/nrc2167 Einhorn, L.H.; Donohue, J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. 1997. J. Urol. 2002, 167, 928–933. Gutekunst, 2013, Cisplatin hypersensitivity of testicular germ cell tumors is determined by high constitutive Noxa levels mediated by Oct-4, Cancer Res, 73, 1460, 10.1158/0008-5472.CAN-12-2876 Mueller, 2006, Loss of Oct-3/4 expression in embryonal carcinoma cells is associated with induction of cisplatin resistance, Tumour Biol, 27, 71, 10.1159/000092324 Harada, 2016, Induction of artificial cancer stem cells from tongue cancer cells by defined reprogramming factors, BMC Cancer, 16, 10.1186/s12885-016-2416-9 Shen, 2014, High Expression of SOX2 and OCT4 Indicates Radiation Resistance and an Independent Negative Prognosis in Cervical Squamous Cell Carcinoma, J Histochem Cytochem, 62, 499, 10.1369/0022155414532654 Liu, 2017, Knockdown of OCT4 may sensitize NSCLC cells to cisplatin, Clin Transl Oncol, 19, 587, 10.1007/s12094-016-1569-y Lu, 2017, Chemotherapeutics-induced Oct4 expression contributes to drug resistance and tumor recurrence in bladder cancer, Oncotarget, 8, 30844, 10.18632/oncotarget.9602 Tsai, 2011, Markedly increased Oct4 and Nanog expression correlates with cisplatin resistance in oral squamous cell carcinoma, J Oral Pathol Med, 40, 621, 10.1111/j.1600-0714.2011.01015.x Bártová, 2011, Recruitment of Oct4 Protein to UV-Damaged Chromatin in Embryonic Stem Cells, PLoS ONE, 6, e27281, 10.1371/journal.pone.0027281 Fong, 2011, A DNA repair complex functions as an Oct4/Sox2 coactivator in embryonic stem cells, Cell, 147, 120, 10.1016/j.cell.2011.08.038 Nathansen, 2021, Oct4 confers stemness and radioresistance to head and neck squamous cell carcinoma by regulating the homologous recombination factors PSMC3IP and RAD54L, Oncogene, 40, 4214, 10.1038/s41388-021-01842-1 Schulz, 2019, Cancer Stem Cells and Radioresistance: DNA Repair and Beyond, Cancers (Basel), 11, 862, 10.3390/cancers11060862 Grenman, 1988, Radiosensitivity of head and neck cancer cells in vitro. A 96-well plate clonogenic cell assay for squamous cell carcinoma, Arch Otolaryngol Head Neck Surg, 114, 427, 10.1001/archotol.1988.01860160071024